{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T21:41:44Z","timestamp":1788126104513,"version":"build-2803163510"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,25]]},"DOI":"10.7759\/cureus.88725","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T12:18:17Z","timestamp":1753445897000},"source":"Crossref","is-referenced-by-count":3,"title":["The Therapeutic Effects of Semaglutide in Congenital Linear Scleroderma"],"prefix":"10.7759","author":[{"given":"Helen","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Elhawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Tarbox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcl.2018.04.002","article-title":"Scleroderma in children and adolescents: localized scleroderma and systemic sclerosis","volume":"65","author":"Li SC","year":"2018","unstructured":"Li SC. Scleroderma in children and adolescents: localized scleroderma and systemic sclerosis. Pediatr Clin North Am. 2018, 65:757-81. 10.1016\/j.pcl.2018.04.002","journal-title":"Pediatr Clin North Am"},{"key":"ref2","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2018-214697","article-title":"Consensus-based recommendations for the management of juvenile localized scleroderma","volume":"78","author":"Zulian F","year":"2019","unstructured":"Zulian F, Martini G, Athreya BH, et al.. Consensus-based recommendations for the management of juvenile localized scleroderma. Ann Rheum Dis. 2019, 78:1019-24.","journal-title":"Ann Rheum Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2006.04.052","article-title":"Congenital localized scleroderma","volume":"149","author":"Zulian F","year":"2006","unstructured":"Zulian F, Vallongo C, de Oliveira SK, et al.. Congenital localized scleroderma. J Pediatr. 2006, 149:248-51. 10.1016\/j.jpeds.2006.04.052","journal-title":"J Pediatr"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20152890","article-title":"Localized scleroderma: clinical spectrum and therapeutic update","volume":"90","author":"Careta MF","year":"2015","unstructured":"Careta MF, Romiti R. Localized scleroderma: clinical spectrum and therapeutic update. An Bras Dermatol. 2015, 90:62-73. 10.1590\/abd1806-4841.20152890","journal-title":"An Bras Dermatol"},{"key":"ref5","article-title":"Dermatology in General Medicine","author":"Fitzpatrick TB","year":"1987","unstructured":"Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg IM, Austen KE. Dermatology in General Medicine. McGraw-Hill, New York (NY); 1987."},{"key":"ref6","article-title":"Effectiveness of medium-dose ultraviolet A1 phototherapy in localized scleroderma","volume":"50","author":"Su O","year":"2011","unstructured":"Su O, Onsun N, Onay HK, et al.. Effectiveness of medium-dose ultraviolet A1 phototherapy in localized scleroderma. Int J Dermatol. 2011, 50:785-91.","journal-title":"Int J Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP-1 receptor agonists","volume":"182","author":"Bendotti G","year":"2022","unstructured":"Bendotti G, Montefusco L, Lunati ME, et al.. The anti-inflammatory and immunological properties of GLP-1 receptor agonists. Pharmacol Res. 2022, 182:106320. 10.1016\/j.phrs.2022.106320","journal-title":"Pharmacol Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2018.03.004","article-title":"The glucagon-like peptide-1 (GLP-1) analog liraglutide attenuates renal fibrosis","volume":"131","author":"Li YK","year":"2018","unstructured":"Li YK, Ma DX, Wang ZM, et al.. The glucagon-like peptide-1 (GLP-1) analog liraglutide attenuates renal fibrosis. Pharmacol Res. 2018, 131:102-11. 10.1016\/j.phrs.2018.03.004","journal-title":"Pharmacol Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2024.1379189","article-title":"Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis","volume":"11","author":"Masson W","year":"2024","unstructured":"Masson W, Lobo M, Nogueira JP, Rodriguez-Granillo AM, Barbagelata LE, Siniawski D. Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis. Front Cardiovasc Med. 2024, 11:1379189. 10.3389\/fcvm.2024.1379189","journal-title":"Front Cardiovasc Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/387474-the-therapeutic-effects-of-semaglutide-in-congenital-linear-scleroderma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T12:18:18Z","timestamp":1753445898000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/387474-the-therapeutic-effects-of-semaglutide-in-congenital-linear-scleroderma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":9,"URL":"https:\/\/doi.org\/10.7759\/cureus.88725","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,25]]}}}